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More than four years have now passed since Dunham et al.
[1] published ‘The DNA sequence of human chromosome
22’, in December 1999. This was the first ‘essentially’ com-
plete human chromosome sequence to be finished. A few
months later, in May 2000, Hattori et al. [2] published ‘The
DNA sequence of human chromosome 21’. At that time it
seemed as though a rapid succession of completed chromo-
somes and their publications were to follow (perhaps in
reverse numerical order, reflecting chromosomal size), but it
wasn’t until almost two years later, in December 2001, that
the completion of chromosome 20 was announced [3]. Since
then, a few more of the remaining chromosomes (succes-
sively 14, Y, 7, 6, 13, 19, 9 and 10) have been published, but
we are still waiting on the rest, hopefully all of which will
appear by the end of this year. With the announcement of
the ‘completion’ of the entire human genome in April 2003,
it’s just a matter of time.
As the first two chromosome sequences have been complete
for a relatively long time (in comparison to the rest of the
chromosomes), now seems an appropriate time to take a look
at how research on these chromosomes, and how genomic
research in general, has been affected. How can we measure
the impact of the completion and publication of the first two
finished chromosomes? By counting the number of times each
chromosome paper has been cited? By detecting an increase in
the number of publications related to each chromosome? By
noticing a shift in the types of research being carried out on
each chromosome? By seeing an increase in the gene count,
or a decrease in the number of unidentified disease genes?
This article takes a brief look at these measures and more,
concluding that the overall number of genes on chromosomes
21 and 22 has not changed much since the initial annotation
of these chromosomes, but experimental verifications have
increased the number of confirmed genes. Furthermore, the
availability of the entire chromosome sequences seems to
have facilitated the localization of some disease loci on chro-
mosomes 21 and 22. 
Numbers of citations
According to the ISI Web of Knowledge [4] (as of October 31
2003), among 3,001 articles and reviews (keywords ‘human
genome’) written from 1999 to 2002, the first two chromo-
some completion papers were among the top ten most-cited.
As expected, the two papers published in 2001 reporting the
human genome draft sequence, by the International Human
Genome Sequencing Consortium [5] and Celera Genomics
[6], were the most-cited, with 2,666 and 2,058 citations,
respectively. Following in third place was the chromosome
22 paper [1], and in seventh the chromosome 21 paper [2]
(on which I am an author), with 558 and 405 citations,
respectively. Only 23 other papers describing large-scale
studies, in areas such as single-nucleotide polymorphisms
Abstract
In the four years since the publication of the first two ‘complete’ human chromosome sequences
the type of research being done on each has shifted subtly, reflecting the impact of genomic data on
biological science in general. There is now considerably more gene-expression evidence to support
predicted genes, and the annotation of functions for previously unknown genes, including those
implicated in disease, is gradually improving. (SNPs), linkage disequilibrium, microarray analysis of gene
expression, and transposable elements, were cited 100 times
or more. 
The types of articles that cited the first two chromosome
publications covered a range of research areas, with the
majority being comparative genomics, comparative
mapping, gene discovery, haplotype analysis, genomic orga-
nization, and chromosome-wide gene expression analysis.
Clearly, the availability of whole, ‘completely’ finished chro-
mosomes made possible some of these new broad-scale
types of research. For example, when doing comparative
genomics to try and identify conserved regions that may
contain regulatory elements, it is essential that both of the
sequences that are being compared be as complete as possi-
ble, in order to minimize the false-negative rate. While the
syntenic regions of these two chromosomes in other species
are not necessarily finished to the same high quality, for
example for mouse, rat and chicken, they are available at
various levels of draft from whole-genome shotgun assem-
blies. Fortunately, in the case of human chromosome 21, the
equivalent chromosome in chimpanzee, chromosome 22, is
now available in high-quality finished form [7], and the same
is being done for regions similar to human chromosome 22.
The number of chromosome-related
publications 
If we look at the number of publications in PubMed [8]
using the search criteria ‘human chromosome 21 OR human
chromosome 22’, the average number of articles per year for
both chromosomes begins to level off in 1990 (106 for chro-
mosome 21 and 83 for chromosome 22), several years
before the sequence publications (Figure 1a). On the basis
of this information, the publications of the first two chro-
mosome sequences had no effect on the number of chromo-
some-related papers published per year. If the number of
publications per chromosome is weighted by chromosome
size (Figure 1b), chromosomes 21 and 22 (as well as chro-
mosomes 17 and 19) appear to be very ‘high impact’ chro-
mosomes. In the case of chromosome 21, this effect could
be due to the special interest in Down syndrome (trisomy
21). If the number of publications per chromosome is
weighted by the number of genes on the chromosome
(Figure 1c), chromosome 21 appears to be very significant,
followed closely by chromosomes 13, 18 and 22. This obser-
vation may be due to the relatively small size of these chro-
mosomes and low numbers of genes in comparison with the
other chromosomes. 
It might have been expected that the number of chromo-
some-related papers would increase after the original publi-
cation of the first chromosome sequences, but instead we see
a shift in the type of research that is being conducted.
Whereas before their publication the research emphasis was
on mapping and novel gene discovery, after their publication
the emphasis turned to comparative analysis (for example,
between mouse and human, as by Pletcher et al. [9]), haplo-
type analysis (for example, by Dawson et al. [10]) and whole-
chromosome transcription analysis (for example, by Rinn et
al. [11]). Hence, the availability of essentially complete, high-
quality sequence is ushering in a whole new era of genomic
research. Individual scientists generally no longer have to
worry about the tedious tasks of mapping, sequencing and
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Figure 1
The publication history of chromosomes 21 and 22. (a) The number of
articles in PubMed [8] that include ‘chromosome 21’ or ‘chromosome 22’
and ‘human’ in their title or abstract. (b) Chromosome publications
weighted by sequence length. The number of publications since June 2000
has been multiplied by a factor of 10 to make the trend more visible.
(c) Chromosome publications weighted by gene content per
chromosome. The number of publications since June 2000 has been
multiplied by a factor of 10 to make the trend more visible. 
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(c)gene identification, but can instead focus their efforts on
finer details of their research, such as functional and regula-
tory analyses. 
Other reasons for the leveling off in publication numbers
could be that the number of researchers interested in these
two chromosomes, and the amount of funding available for
studying them, has not changed in recent years. And,
because of the International Human Genome Sequencing
Consortium’s adherence to the ‘Bermuda rules’ [12],
researchers around the world were able to access the
sequence as it was being produced: they didn’t have to wait
until the chromosomes (or worse yet, the whole genome!)
were published to utilize it. If this policy had not been imple-
mented, we might have seen a spike in the number of chro-
mosome-related publications upon publication and release
of the sequence, assuming that researchers were eager to
make use of it.
The number of genes
Another measure of the significance of the publications of
the first full chromosome sequences might be the number of
genes that have been identified since the original publica-
tions. When the sequences of chromosomes 21 and 22 were
first published, it is safe to assume that the papers’ authors
did not believe that they had identified all of the genes on
these chromosomes. They (we) knew that, upon release of
the data, other scientists would identify more genes, and that
new information would become available to help verify and
append the initial annotations - and this is exactly what has
taken place over the past four years. If we look at the number
of genes (total non-pseudogenes) for each chromosome at
the time of publication and compare it to the most recently
available counts (Table 1), we can see that overall the gene
numbers have not risen that dramatically - an indication
that the initial gene identification was done very well. In the
case of chromosome 21 there is quite a jump in number of
genes, but this is mainly due to the annotation of two
keratin-associated protein gene clusters, one of which was
only counted as a single gene in the original analysis. 
We can also see that for both chromosomes the number of
genes in the ‘known’ category has dramatically increased,
while the number of ‘novel’ and ‘putative’ genes has generally
decreased (Table 1). This re-categorization is due in part to the
number of experimental verifications that have since been
carried out on the predicted genes, and in part to the signifi-
cant increase in number of full-length cDNAs and expressed
sequence tags (ESTs) that have recently been deposited in the
public databases. Many more human genes are now covered
by at least one of these valuable mRNA resources than when
the chromosomes were first annotated; four years ago mRNA
data were much scarcer, and many gene models were based on
partial EST evidence or solely on in silico gene-prediction
analysis. At that time, for each chromosome only one repre-
sentative model was annotated per gene; because of all the
new mRNA data, however, roughly 30-40% of genes now have
multiple transcripts annotated. And, also because of the new
mRNA data, most annotators now agree that, in order to keep
the number of false-positive gene models to a minimum,
computer-only gene predictions should not become part of the
annotation set until they are experimentally verified. Another
noticeable change that can be seen in Table 1 is the near dou-
bling in the number of pseudogenes for both chromosomes.
This jump is due to several factors, including the increase in
mRNA data, the completion of the rest of the human genome
and subsequent improvement of annotation elsewhere within
the genome, and the development of standards on how to
define pseudogenes.
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Table 1
Original and current gene catalogs for human chromosomes 21 and 22
Gene category Chromosome 21 Chromosome 22
May 2000 [2] February 2004 [16 ] December 1999 [1] January 2003 [13]
Known 127 241 247 393
Novel coding sequences  13 1 150 153
Novel transcripts 17 25 0 0
Putative 68 17 148 31
Total non-pseudogenes 225 284 545 577
Pseudogenes 59 98 134 234
Total 284 382 679 811
Immunoglobulin segments (all types)* 125
Grand total  936
*Chromosome 22 contains the human immunoglobulin lambda gene locus, which is a very complex region consisting of active and inactive (pseudogene)
immunoglobulin gene segments.Annotation of genomes is an evolving process that improves
with time as additional experiments, tools, and resources
become available. In the same way as Collins et al. [13] have
now published the first follow-up to their initial annotation
of chromosome 22, annotation of the other chromosomes is
sure to improve over time (of course, for those chromosomes
that are not yet published we should expect that the first-
pass annotation is up to current standards). Researchers
from the human genome community are working together to
standardize gene and genome annotation. In March 2002,
the first Human Annotation Workshop (HAWK) [14] was
held at The Wellcome Trust Sanger Institute, bringing
together scientists from most of the public sequencing
centers, various databases, and the Human Genome Organi-
zation (HUGO) Nomenclature Committee (HGNC) [15]. The
goals of the workshop were to establish communication
between the groups involved in annotation, to standardize
the way annotation is done across the human genome, and
to exchange information, all with the aim of producing the
highest standards of manual curation for the human
genome. It should be noted that the HGNC has the daunting
task of assigning unique identifiers, or gene symbols, to each
gene in the human genome, thus reducing the amount of
confusion often associated with multiple and non-unique
gene names. 
The number of disorders characterized 
If we look at the number of human diseases and disorders
(26 and 62, respectively) that have been mapped to chro-
mosomes 21 and 22 (see Table 2, 3 and 4), we find that 3
(12%) and 12 (19%), respectively, were not mapped to the
chromosomes until after January 2000. Thus, it appears
that the availability of the entire chromosome sequences
was necessary for locating some disease loci. Even now that
all of these disorders have been mapped to their respective
chromosomes, determining the exact location of the disease
locus, the full-length cDNA product, and the mutation(s)
that correlates phenotype and genotype remains a challenge.
In the case of chromosome 21, 6 (23%, including Down syn-
drome) out of 26 disorders do not have any conclusive muta-
tion identified, and 4 disorders (15%) do not yet have any
specific sequence location. And, for chromosome 22, an
amazing 30 (48%) out of 62 disorders do not have any con-
clusive mutation identified, and 14 disorders (23%) do not
yet have any specific sequence location; but several of the
disease loci on chromosome 22 are involved in chromosomal
rearrangement disorders, which are difficult to pinpoint,
such as chronic myeloid leukemia. Two of the biggest barri-
ers to identifying disease-gene locations and mutations are
the lack of patient (and family) samples and complexity of
the disease, particularly in multi-gene disorders such as
Down syndrome or heterogeneous disorders such as schizo-
phrenia and Alzheimer’s disease. By having the full human
genome sequence available, investigators need only to con-
centrate on matching disease phenotypes with genes from
the current annotation, rather than having to identifying the
genes themselves.
In Tables 3 and 4, all the currently mapped disorders for both
chromosomes 21 and 22 are listed, along with information
about how many related publications there have been for
each disorder in total and since the publication of the respec-
tive chromosome sequence. While some genes, such as the
amyloid   a4 precursor protein (APP; 132 publications in
total and 39 since [2]) on chromosome 21, have been of
research interest for a long time, other genes, such as CHEK2
(Li-Fraumeni syndrome; 24 publications in total and 20 since
[1]) on chromosome 22, have come into focus since the publi-
cation of the chromosome sequence. Some of the genes, such
as OGS2 (Opitz G syndrome, type II; 60 publications in total),
have had no significant publications since the chromosome
sequence was published, and other, such as TMPRSS3 (child-
hood-onset neurosensory deafness; four publications in
total), have only had papers published since the chromo-
some-sequence papers. Of course, some disorders, such as
Down syndrome on chromosome 21 and DiGeorge syndrome
on chromosome 22, continue to be the focus of much
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Table 2 
The history of disease-related loci currently mapped to chromosomes 21 and 22
Chromosome 21 (26 disorders) Chromosome 22 (62 disorders)
To December 1999 From January 2000 Pending To December 1999 From January 2000 Pending
Mapped to chromosome 23  (88%) 3 (12%) 0 (0%) 50  (81%)  12  (19%)  0  (0%)
Mutation identified 15 (58%) 5 (19%) 6 (23%) 23  (37%) 9 (15%) 30 (48%)
First gene sequence published 22 (85%) 0 (0%) 4 (15%) 42  (68%) 6 (10%) 14 (23%)
Full-length cDNA published 20 (77%) 2 (8%) 4 (15%) 39  (63%) 7 (11%) 16 (26%)
There are currently 26 disorders mapped to chromosome 21, and 62 disorders mapped to chromosome 22. Numbers indicate the date by which the
loci were first mapped to the chromosomes, when the first phenotype-related mutations were identified, when the first gene sequences were published,
and when the first full-length cDNAs were published. Since exact date information was not available, a cutoff of January 2000 was used. Data were
obtained from the NCBI resources OMIM [17], GenBank [18] and LocusLink [19].research, even though the exact gene (or genes) that cause
these syndromes has not yet been pinned down.
In summary, depending on how impact is measured, the
publications of the first two finished human chromosomes
may or may not appear to be significant, although one would
have a hard time arguing against significance. From the
analysis here, each chromosome has had various influences
on the research that is being done on that particular chro-
mosome and in other areas of biological research. Although
the authors may not have done everything the ‘right’ way
the first time around, they certainly set a standard for how
other chromosomes should be finished, annotated and
maintained over time. Given that both of the first-finished
chromosomes are relatively small (each representing about
1.5% of the entire genome) they have subsequently become
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Table 3 
Disease-related loci currently mapped to chromosome 21
Total Publications 
Gene symbol publications since [2] OMIM number Disorder
APP 132 39 (30%) 104760 Cerebroarterial, Dutch type amyloidosis; APP-related Alzheimer disease-1; chronic 
schizophrenia
CBS 132 14 (11%) 236200 B6-responsive and nonresponsive comocystinuria; hyperhomocysteinemic thrombosis 
SOD1 129 27 (21%) 147450 Amytrophic lateral sclerosis due to SOD1 deficiency
ITGB2 68 5 (7%) 600065 Leukocyte adhesion deficiency
DCR 44 5 (11%) 190685 Down syndrome
HPE1 40 5 (13%) 236100 Holoprosencephaly-1
RUNX1 28 6 (21%) 151385 Acute myeloid leukemia; familial platelet disorder with associated myeloid malignancy
COL6A1 28 4 (14%) 120220 Bethlem myopathy
HLCS 28 2 (7%) 253270 Biotin-responsive and biotin-unresponsive multiple carboxylase deficiency 
AIRE 23 10 (43%) 607358 Autoimmune polyglandular disease, type I
PFKL 20 0 (0%) 171860 Hemolytic anemia due to phosphofructokinase deficiency
CRYAA 19 3 (16%) 123580 Cataract, zonular central nuclear, autosomal dominant; cataract, congenital 
progressive, autosomal recessive; cataract, autosomal dominant nuclear
KCNE1 18 2 (11%) 176261 Jervell and Lange-Nielsen syndrome; long QT syndrome-5
CSTB 17 2 (12%) 601145 Progressive myoclonic epilepsy 1
COL18A1 14 6 (43%) 120328 Knobloch syndrome
DYRK1A 10 2 (20%) 600855 Possible triplicate state responsible for mental defect in Down syndrome
COL6A2 94  ( 44%) 120240 Bethlem myopathy; Ullrich scleroatonic muscular dystrophy
IFNGR2 8 0 (0%) 147569 Atypical, familial disseminated mycobacterial infection
TAM 6 0 (0%) 159595 Transient leukemia of Down syndrome
PRSS7 5 1 (20%) 606635 Enterokinase deficiency
TMPRSS3 44 ( 100%) 605511 Autosomal recessive childhood onset deafness 8; congenital autosomal recessive 
deafness 10 
SLC5A3 4 0 (0%) 600444 {Possible role in Down syndrome}
FTCD 31  ( 33%) 606806 Glutamate formiminotransferase deficiency
CLDN14 21  ( 50%) 605608 Autosomal recessive deafness 29
KCNE2 1 0 (0%) 603796 Long QT syndrome-6
USH1E 1 0 (0%) 602097 Usher syndrome, type 1E
The total number of relevant papers and the number of relevant papers since the chromosome 21 publication [2] are listed. A bold number indicates that
there were ten or more post-chromosome locus-related publications; an italic percentage indicates that 25% or more of all locus-related publications
appeared after the chromosome sequence was published. Curly brackets indicate examples of mutations that lead to universal susceptibility to a specific
infection (diphtheria or polio), to frequent resistance to a specific infection (vivax malaria), protection from nicotine addiction, or other susceptibilities.
Data were obtained from the NCBI resources OMIM [17] and PubMed [8].111.6 Genome Biology 2004, Volume 5, Issue 7, Article 111 Taylor http://genomebiology.com/2004/5/7/111
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Table 4 
Disease-related loci currently mapped to chromosome 22
Total Publications 
Gene symbol publications since [1] OMIM number Disorder
DGCR 91 18 (20%) 188400 DiGeorge syndrome; velocardiofacial syndrome
DIA1 80 5 (6%) 250800 Methemoglobinemia, type I; methemoglobinemia, type II
CYP2D 75 7 (9%) 124030 Debrisoquine sensitivity; {possible susceptibility to Parkinsonism}
BCR 71 18 (25%) 151410 Chronic myeloid leukemia; acute lymphocytic leukemia
OGS2 60 0 (0%) 145410 Opitz G syndrome, type II
NF2 56 22 (39%) 607379 Neurofibromatosis, type 2; NF2-related somatic meningioma; schwannomatosis
TCN2 53 3 (6%) 275350 Transcobalamin II deficiency
CTLO 51 9 (18%) 218040 Possibly Costello syndrome
ARSA 51 5 (10%) 607574 Metachromatic leukodystrophy
COMT 48 13 (27%) 116790 {Possible susceptibility to schizophrenia}
CECR 48 1 (2%) 115470 Cat eye syndrome
PDGFB 39 2 (5%) 190040 SIS-related meningioma; dermatofibrosarcoma protuberans; giant-cell fibroblastoma
EWSR1 38 1 (3%) 133450 Ewing sarcoma; neuroepithelioma; extraskeletal myxoid chondrosarcoma
CHEK2 24 20 (83%) 604373 Li-Fraumeni syndrome; somatic osteosarcoma; {possible susceptibility to breast 
cancer}; familial prostate cancer; {possible susceptibility to breast and colorectal 
cancer}
SOX10 24 10 (42%) 602229 Waardenburg-Shah syndrome; Yemenite deaf-blind hypopigmentation syndrome; 
neurologic variant Waardenburg-Shah syndrome
NAGA 23 1 (4%) 104170 Schindler disease; Kanzaki disease; mild NAGA deficiency
ACF 21 1 (5%) 125520 Cayler cardiofacial syndrome
MYH9 20 12 (60%) 160775 May-Hegglin anomaly; Fechtner syndrome; Sebastian syndrome; autosomal dominant
deafness 17; Epstein syndrome
EP300 16 8 (50%) 602700 Colorectal cancer
TIMP3 16 6 (38%) 188826 Sorsby fundus dystrophy
SMARCB1 16 3 (19%) 601607 Rhabdoid tumors; rhabdoid familial predisposition syndrome
CTHM 16 2 (13%) 217095 ? Conotruncal cardiac anomalies
SCZD4 15 2 (13%) 600850 {Possible susceptibility to schizophrenia}
ADSL 15 2 (13%) 608222 Adenylosuccinase deficiency
NEFH 15 0 (0%) 162230 {Possible susceptibility to amyotrophic lateral sclerosis}
SLC5A1 15 0 (0%) 182380 Glucose/galactose malabsorption
CRYBB2 12 2 (17%) 123620 Cataract, cerulean, type 2; cataract, sutural, with punctate and cerulean opacities
GGT1 12 0 (0%) 231950 Glutathioninuria
A4GALT 11 5 (45%) 607922 [Blood group, P system]
HMOX1 11 5 (45%) 141250 Heme oxygenase-1 deficiency
CSF2RB 11 1 (9%) 138981 Pulmonary alveolar proteinosis
ACR 11 0 (0%) 102480 {Possible male infertility due to acrosin deficiency}
MLC1 10 8 (80%) 605908 Megalencephalic leukoencephalopathy with subcortical cysts
SCA10 10 5 (50%) 603516 Spinocerebellar ataxia-10
FBLN1 10 2 (20%) 135820 Synpolydactyly, 3/3’4, associated with metacarpal and metatarsalsynostoses
GP1BB 9 1 (11%) 138720 Bernard-Soulier syndrome, type B; isolated giant platelet disorder
HCF2 9 0 (0%) 142360 Thrombophilia due to heparin cofactor II deficiency
RAC2 86 ( 75%) 602049 Neutrophil immunodeficiency syndromethe test subjects of many other types of research, such as
whole-chromosome gene-expression [11] and haplotype
analysis [10]. Given the continuing number of publications
that come out each year related to chromosomes 21 and 22,
there should be no doubt that the availability of these com-
plete sequences has had a lasting influence on many areas
of research.
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Table 4 (continued)
Total Publications 
Gene symbol publications since [1] OMIM number Disorder
PRODH 85 ( 63%) 606810 Hyperprolinemia, type I; {possible susceptibility to schizophrenia}
GGT2 8 0 (0%) 137181 [Familial high serum gamma-glutamyltransferase] 
HIRA 8 0 (0%) 600237 {Possible role in CATCH22} 
IGLL1 7 1 (14%) 146770 Autosomal agammaglobulinemia recessive
APOL1 65 ( 83%) 603743 {Possible susceptibility to schizophrenia}
XBP1 64 ( 67%) 194355 {Possible susceptibility to schizophrenia}
SCO2 64 ( 67%) 604272 Fatal infantile cardioencephalomyopathy due to cytochrome coxidase deficiency
ECGF1 62 ( 33%) 131222 Myoneurogastrointestinal encephalomyopathy syndrome
PVALB 6 1 (17%) 168890 {Possible role in DiGeorge syndrome}
APOL2 44 ( 100%) 607252 {Possible susceptibility to schizophrenia}
APOL4 44 ( 100%) 607254 {Possible susceptibility to schizophrenia}
MKL1 44 ( 100%) 606078 Acute megakaryoblastic leukemia
LARGE 43 ( 75%) 603590 {Possibly meningioma}
HPS4 43 ( 75%) 606682 Hermansky-Pudlak syndrome
SYN3 41 ( 25%) 602705 {Possible relation to schizophrenia}
KAZA 33 ( 100%) 608207 {Possible susceptibility to Kala-azar}
PSAP2 32 ( 67%) 606230 Chromosome 22q13.3 deletion syndrome
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